Splicing dysregulation in cancer: from mechanistic understanding to a new class of therapeutic targets  

作　　者：Yongbo Wang Yufang Bao Sirui Zhang Zefeng Wang 

机构地区：[1]Department of Cellular and Genetic Medicine,School of Basic Medical Sciences,Fudan University,Shanghai 200032,China [2]CAS Key Laboratory of Computational Biology,CAS-MPG Partner Institute for Computational Biology,Shanghai Institute of Nutrition and Health,CAS Center for Excellence in Molecular Cell Science,University of Chinese Academy of Sciences,Chinese Academy of Sciences,Shanghai 200031,China

出　　处：《Science China(Life Sciences)》2020年第4期469-484,共16页中国科学（生命科学英文版）

基　　金：supported by the National Natural Science Foundation of China (81871878 and 31371299 to Y.B.W.;31730110, 31661143031, and 31570823 to Z.F.W.);supported by the type A CAS Pioneer 100-Talent Program.

摘　　要：RNA splicing dysregulation is widespread in cancer. Accumulating evidence demonstrates that splicing defects resulting from splicing dysregulation play critical roles in cancer pathogenesis and can serve as new biomarkers and therapeutic targets for cancer intervention. These findings have greatly deepened the mechanistic understandings of the regulation of alternative splicing in cancer cells, leading to rapidly growing interests in targeting cancer-related splicing defects as new therapies. Here we summarize the current research progress on splicing dysregulation in cancer and highlight the strategies available or under development for targeting RNA splicing defects in cancer.RNA splicing dysregulation is widespread in cancer. Accumulating evidence demonstrates that splicing defects resulting from splicing dysregulation play critical roles in cancer pathogenesis and can serve as new biomarkers and therapeutic targets for cancer intervention. These findings have greatly deepened the mechanistic understandings of the regulation of alternative splicing in cancer cells, leading to rapidly growing interests in targeting cancer-related splicing defects as new therapies. Here we summarize the current research progress on splicing dysregulation in cancer and highlight the strategies available or under development for targeting RNA splicing defects in cancer.

关 键 词：SPLICING ALTERNATIVE SPLICING CANCER RNA THERAPEUTICS 

分 类 号：R730.2[医药卫生—肿瘤]